# Reducing the incidence of febrile neutropenia in cancer patients treated with chemotherapy with PointCheck: a portable non-invasive neutropenia analyzer

> **NIH NIH R44** · LEUKO LABS, INC. · 2020 · $1,182,313

## Abstract

PROJECT SUMMARY
The goal of this Phase II SBIR project is to optimize and validate PointCheck, the first non-invasive
point-of-care (POC) device that identifies patients undergoing cancer chemotherapy who have early-
stage febrile neutropenia and need immediate treatment to prevent serious infections. Every year in the
US, 650,000 cancer patients are treated with chemotherapy. One side effect of treatment is neutropenia, a life-
threatening condition caused by low levels of neutrophils that leads to hospitalization, increased risk of
mortality and total associated costs of $2.7B annually. PointCheck uses noninvasive optical imaging of
microcirculation in nailfold capillaries to detect severe neutropenia without the need for a blood sample. It is
intended for use by cancer patients undergoing chemotherapy, in order to identify patients with neutropenia
who require prompt treatment to avoid serious infections, hospital readmission costs and morbidity. Because it
is self-contained and does not require blood sampling or reagents, it ultimately may be used by patients at
home to monitor blood counts between chemotherapy sessions.
In Phase I of this project, Leuko Labs successfully: (1) automated the selection of suitable capillaries from raw
videos; (2) automated the detection of flow gaps that indicate passage of neutrophils in nail-fold capillaries; and
(3) automatically analyzed manually-collected 1-min videos of nailfold capillaries from 44 cancer chemotherapy
patients and identified those with grade IV neutropenia (<500 neutrophils/mm3) with an excellent classification
performance (AUC=0.95).
The objective of this Phase II project is to complete the next steps to bring PointCheck to market by designing
a production-ready PointCheck device and validating it in a clinical study to support the filing of a Class II De
Novo approval to the FDA. Aim 1 is to design a production-ready PointCheck hardware prototype for
unsupervised use by patients by miniaturizing the optical components. Aim 2 is to develop and integrate the
image analysis software pipeline to the production-ready unit. Aim 3 is to complete an initial pilot usability study
performed in 3 cohorts of 30 patients (n=90 total) as the device is optimized in Aims 1 and 2; this study will
also confirm that PointCheck is ready for the pivotal clinical study in Aim 4. Aim 4 is to complete a pivotal
clinical study to validate PointCheck in a clinical diagnostic study (n=100) to confirm that grade IV neutropenia
can be identified safely and effectively. Aim 5 is to submit a Class II De Novo approval package to the FDA.
Successful completion of this Phase II project will fulfill the requirements for a minimum viable product and
enable initial commercialization of this first-in-kind technology to improve the management of febrile
neutropenia in cancer patients undergoing chemotherapy.

## Key facts

- **NIH application ID:** 10010951
- **Project number:** 2R44CA228920-02A1
- **Recipient organization:** LEUKO LABS, INC.
- **Principal Investigator:** Carlos Castro-Gonzalez
- **Activity code:** R44 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $1,182,313
- **Award type:** 2
- **Project period:** 2018-07-12 → 2022-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10010951

## Citation

> US National Institutes of Health, RePORTER application 10010951, Reducing the incidence of febrile neutropenia in cancer patients treated with chemotherapy with PointCheck: a portable non-invasive neutropenia analyzer (2R44CA228920-02A1). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10010951. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*